معرفی
Bridget King is a Doctor of Philosophy specializing in Psychosis Studies with significant research contributions in the fields of COVID-19 complications, sleep disorders, and schizophrenia. Her work appears in high-impact journals including Immunity and Ageing, The Lancet, and Molecular Psychiatry. She is actively involved in the PHOSP-COVID Study collaborative group and has 87 citations across her research portfolio.
Dr. King's research interests center around the intersection of mental health and physical health outcomes, particularly focusing on psychosis studies, brain glutamate levels in schizophrenia, and the long-term effects of COVID-19 including dyspnea and sleep disturbances. Her work contributes to several UN Sustainable Development Goals related to health and well-being.
Her recent publications demonstrate a strong focus on understanding the mechanisms behind post-COVID symptoms, immune aging in relation to disease severity, and the neurobiological aspects of psychosis. The research spans both clinical studies with patient cohorts and meta-analyses synthesizing existing knowledge in the field.
- 28 citations for her work on sleep disturbance and dyspnea following COVID-19
- 32 citations for her meta-analysis on brain glutamate levels in schizophrenia
- 19 citations for her research on post-COVID dyspnea recovery
- 8 citations for her immune aging and COVID-19 severity study
Dr. King collaborates extensively with researchers across multiple institutions as evidenced by her participation in large collaborative groups. Her work has been picked up by numerous news outlets and discussed widely on social media platforms, indicating significant impact in both academic and public spheres.
